Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

Poupak Fallahi,1 Silvia Martina Ferrari,2 Giusy Elia,2 Francesca Ragusa,2 Sabrina Rosaria Paparo,2 Ilaria Ruffilli,2 Armando Patrizio,2 Gabriele Materazzi,3 Alessandro Antonelli21Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 2D...

Full description

Bibliographic Details
Main Authors: Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Materazzi G, Antonelli A
Format: Article
Language:English
Published: Dove Medical Press 2019-08-01
Series:Cancer Management and Research
Subjects:
MTC
pediatric MTC
vandetanib
RET
VEGFR
EGFR
DTC
AEs
calcitonin
CEA.
Online Access:https://www.dovepress.com/evaluating-vandetanib-in-the-treatment-of-medullary-thyroid-cancer-pat-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/evaluating-vandetanib-in-the-treatment-of-medullary-thyroid-cancer-pat-peer-reviewed-article-CMAR

Similar Items